McKesson Corporation (MCK) stock analysis

Healthcare · Medical Distribution

From the 10-K filed 2026-05-08

Business type: Franchise

How it makes money

It generates profit by distributing branded and generic drugs and providing clinical services through the US Oncology Network and its ClarusONE sourcing venture.

The North American Pharmaceutical segment is the primary volume driver, distributing products across U.S. and Canadian channels including retail national accounts and institutional providers.

Profitability is enhanced by high-value specialty services in the Oncology & Multispecialty segment, which manages physician-led networks and clinical research through the Sarah Cannon Research Institute. It also leverages the Prescription Technology Solutions segment to connect biopharma brands with 50,000 pharmacies and 1,000,000 providers for prior authorization and price transparency.

What growth costs

It invested $2.5 billion to acquire a 70% interest in Core Ventures and $170 million in restructuring to improve operational efficiency.

Growth is driven by large-scale acquisitions in specialty care, such as the $875 million purchase of an 80% interest in PRISM Vision.

Maintaining the business requires continuous capital investment in distribution center automation, AI-driven data analytics, and the physical replenishment of a 270,000-product medical-surgical inventory. It is also incurring costs to separate its Medical-Surgical Solutions segment into an independent company, including a $1.25 billion investment from Apollo Funds.

What could damage it

Changes to the 340B Drug Pricing Program or implementation of the Inflation Reduction Act could compress margins by reducing pharmaceutical reimbursement and pricing.

The business faces structural risks from government policies designed to lower drug costs, such as the Inflation Reduction Act's drug price negotiations and the One Big Beautiful Bill's impact on Medicaid funding. Additionally, manufacturers may restrict sales under the 340B program or modify service agreements due to new CMS rules on bona fide service fees, potentially bypassing McKesson's role as a wholesale intermediary.

About McKesson Corporation

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, hospital reference labs, nursing homes, hospice and home health care agencies, government facilities, and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

More on MCK

Other companies in Medical Distribution